MD Anderson Cancer Center
Colin P. N. Dinney is Professor and Chairman of the Department of Urology at The University of Texas M. D. Anderson Cancer Center (MDACC). After completing his residency in urology at Dalhousie University in Halifax, Nova Scotia, Dr. Dinney spent two years in a postdoctoral fellowship with Dr. Isaiah Fidler at MDACC studying immunotherapy of renal cell carcinoma and won the Canadian Urological Association Research Award for this work. Dr. Dinney then turned his attention to bladder cancer and developed models for metastatic bladder cancer that he used to study the biology of bladder cancer metastasis. After completing his clinical fellowship, Dr. Dinney joined the faculty at MDACC, and while maintaining an active clinical practice, Dr. Dinney directs an active research program and continues to make significant contributions to the development of novel therapy for both early and advanced bladder cancer. He is the PI of the MDACC SPORE in Bladder Cancer, which first received funding in 2001. In addition to overseeing this program, he is actively engaged in SPORE-related translational research. Over the past 15 years several concepts developed in his laboratory have been translated into clinical studies, and his work to develop intravesical interferon gene therapy for non-muscle invasive bladder cancer has moved beyond the SPORE to a Phase III trial conducted by the SUO Clinical Trials Consortium (CTC). Through his collaborations at MDACC, the NCI, the SUO, and with industry, Dr. Dinney continues to substantially expand the efforts to develop novel therapies for bladder cancer.
Amongst other administrative positions, Dr. Dinney is the Past President of the SUO CTC. Dr. Dinney serves as the SPORE Liaison to SWOG’s GU Executive Committee, and is the Urology chair of the NIH GU Steering Committee Bladder Cancer Task Force.
Saturday, May 4
3:27 PM – 3:33 PM